MDM4

Overview

MDM4 (also known as MDMX) is a critical negative regulator of the p53 tumor suppressor. It inhibits p53-mediated transcriptional activation and is frequently overexpressed or amplified in human cancers, contributing to p53 inactivation.

Alterations observed in the corpus

• Amplification/Alteration: Found in 7% of glioblastoma cases as a component of the p53 signaling pathway PMID:18772890.
• Copy number amplifications enriched in breast cancer metastases compared to primary tumors PMID:36585450
• MDM4 amplification detected in breast cancer within the METABRIC cohort of ~2,000 tumors, contributing to p53 pathway dysregulation PMID:22522925
• Focal amplification identified in clear cell renal cell carcinoma (ccRCC) by TCGA comprehensive molecular characterization PMID:23792563
• Recurrent focal amplification in GBM; chr12 double-minute amplification of MDM2/CDK4 was identified as a striking structural finding; MDM4 amplification occurs alongside MDM2/CDK4 in the Rb/p53 pathway PMID:24120142
• Amplification co-identified with MDM2 in 8 NSCLC patients; no significant difference in PFS on anti-PD-(L)1 therapy (HR 1.4, P=.44); hyperprogression signal not reproduced in this cohort PMID:29337640

Cancer types (linked)

• Glioblastoma (GB): Identified as one of the core alterations in the p53 pathway, which is affected in 78% of GBM cases PMID:18772890.

Sources

• PMID:18772890

This page was processed by crosslinker on 2026-05-09. - PMID:36585450

This page was processed by crosslinker on 2026-05-09. - PMID:22522925

This page was processed by crosslinker on 2026-05-09. - PMID:23792563

This page was processed by crosslinker on 2026-05-09. - PMID:24120142

This page was processed by crosslinker on 2026-05-09. - PMID:29337640

This page was processed by wiki-cli on 2026-05-15.